Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists

July 2, 2026

Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of psychiatric and neurological disorders.

BioWorld Science Neurology/psychiatric Patents

Today's news in brief

BioWorld

BioWorld briefs for July 2, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 30, 2026

Illustration demonstrating gut-brain axis

CINP 2026: Gut microbiota could predict antidepressant response

BioWorld

The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to...

Ascending BCI systems deepen national security, ethical concerns

BioWorld

Ready or not, the future has arrived. Novel AI and brain-computer interface (BCI) systems are no longer confined to the realm of science fiction. As an...

Black wavy lines forming an abstract sound wave.png

Deep brain stimulation from the shallows: tomorrow’s BCI technology?

BioWorld

Deep brain stimulation (DBS) through implanted electrodes has enabled fundamentally new ways of treating certain disorders. More than 100,000 severely ill...